UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
(Exact Name of Registrant as Specified in Charter) |
|
| |||
(State or Other Jurisdiction |
| (Commission File Number) |
| (IRS Employer |
of Incorporation) |
|
|
| Identification No.) |
| ||
(Address of Principal Executive Offices) |
| (Zip Code) |
Registrant’s telephone number, including area code: (
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered under Section 12(b) of the Exchange Act: none
Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On December 30, 2022, Leo Ehrlich, Chief Executive Officer of Innovation Pharmaceuticals Inc. (the “Company”), surrendered 11,307,527 shares of the Company’s Class B common stock to the Company for individual tax planning purposes. Mr. Ehrlich received no consideration for the surrender of the shares.
Following the surrender of the shares, 4,333,936 shares of Class B common stock remain outstanding, all of which are held by Mr. Ehrlich. Each share of Class B common stock entitles the holder to ten votes per share and each share of Class A common stock entitles the holder to one vote per share on all matters submitted to the Company’s stockholders for a vote. The Class B common stock is convertible at any time by the holder into shares of Class A common stock on a share-for-share basis.
2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
INNOVATION PHARMACEUTICALS INC. | |||
| Dated: January 4, 2023 | By: | /s/ Leo Ehrlich | |
| Name: | Leo Ehrlich | |
| Title: | Chief Executive Officer | ||
3 |
Cover |
Dec. 30, 2022 |
|---|---|
| Cover [Abstract] | |
| Entity Registrant Name | INNOVATION PHARMACEUTICALS INC. |
| Entity Central Index Key | 0001355250 |
| Document Type | 8-K |
| Amendment Flag | false |
| Entity Emerging Growth Company | false |
| Document Period End Date | Dec. 30, 2022 |
| Entity Incorporation State Country Code | NV |
| Entity File Number | 001-37357 |
| Entity Tax Identification Number | 30-0565645 |
| Entity Address Address Line 1 | 301 Edgewater Place |
| Entity Address Address Line 2 | Suite 100 |
| Entity Address City Or Town | Wakefield |
| Entity Address State Or Province | MA |
| Entity Address Postal Zip Code | 01880 |
| City Area Code | 978 |
| Local Phone Number | 921-4125 |
| Written Communications | false |
| Soliciting Material | false |
| Pre Commencement Tender Offer | false |
| Pre Commencement Issuer Tender Offer | false |